NEW YORK, NY - 
(NewMediaWire) - July 28, 2024 -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against DexCom, Inc. (DXCM) (“DexCom” or the “Company”) (NASDAQ: DXCM).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
On July 25, 2024, after the market closed, DexCom issued a press release reporting its second quarter 2024 financial results. In the press release, the Company lowered its full year 2024 revenue to between $4 billion and $4.05 billion compared to its prior guidance range of between $4.20 billion and $4.35 billion “to account for certain unique items impacting 2024 seasonality.” The press release also quotes DexCom’s Chairman, President and CEO as stating “our execution did not meet our high standards.”
Following this news, the price of DexCom stock price fell $43.85 per share, over 40%, to close at $64 per share on July 26, 2024.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
E-mail: pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
